Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zastaprazan (Primary) ; Esomeprazole
  • Indications Erosive oesophagitis; Heartburn
  • Focus Registrational; Therapeutic Use
  • Acronyms ZERO-1
  • Sponsors Onconic Therapeutics

    • Most Recent Events

    • 01 Feb 2025 Results assessing the efficacy and safety of zastaprazan compared with esomeprazole in patient with erosive esophagitis (EE) were published in the American Journal of Gastroenterology.
    • 27 Aug 2024 Status changed from recruiting to completed.
    • 29 May 2024 According to an Onconic Therapeutics media release, data from the study were presented at Digestive Disease Week (DDW) 2024, held in Washington D.C. from May 18-21, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top